OREANDA-NEWS.  uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr. Garen has more than 20 years of experience in business development within the pharmaceutical sector, having previously held senior positions at Actavis plc, Forest Laboratories, Inc. and Pharmacia Corporation.  Mr. Garen will be responsible for strategic transactions at uniQure, with a focus on business development and alliance management.  Mr. Garen will report to Daniel Soland, Chief Executive Officer of uniQure, and will be based in the Company's Lexington, Massachusetts facility.   

"Jon has an accomplished track record in driving business development initiatives and executing value-generating strategic transactions," said Mr. Soland. "Collaborations, licenses and other corporate development initiatives are a vital part of our growth strategy at uniQure, and Jon's vast experience will be instrumental as we further develop and execute our corporate strategy."

"I am very pleased to be joining uniQure at this important time for the company," stated Jonathan Garen.  "There are tremendous opportunities ahead as we further advance our gene therapy clinical programs and research pipeline, and I look forward to working with Dan and the leadership team to maximize our strategic opportunities."

Mr. Garen was most recently with Syros Pharmaceuticals, Inc., a venture-backed company developing medicines that control genes, where he served as Chief Business Officer.  Prior to joining Syros, he was Assistant Vice President, Business Development at Forest Laboratories, Inc. from 2003 to 2014, and subsequently held the same position at Actavis plc following its acquisition of Forest Laboratories.  Earlier in his career, Mr. Garen was Director of Global Licensing with Pharmacia Corporation and a Founder and Vice President of Technology Exchange, Inc. 

Mr. Garen holds a Master of Environmental Science degree from Yale University and a Bachelor of Science degree in Physics from Massachusetts Institute of Technology.   

About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases.